Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) has exploded upwards after the Company announced it has received encouraging results in its preclinical study showing one of its proprietary cannabinoid compounds causing higher rate of cancer cell death compared to traditional chemotherapy.
This is huge news for Cannabics which is the kind of stock Investors can easily get excited about; CNBX is a runner that loves to make big movies making a spectacular run in early 2017 and another on in early 2018.
Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) bills itself as a U.S public company that has developed a platform which leverages novel drug-screening tools and artificial intelligence to develop cannabinoid-based therapies for cancer that are more precise to a patient’s genetic profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. Cannabics is focusing on natural cannabinoids and its R&D open its doors for collaboration in the discovery of new anticancer compounds.
On July 31, 2014, Cannabics Pharmaceuticals Inc. filed its exclusive Patent Application with the US Patent & Trademark Office (USPTO), which covers the proprietary technology developed by its team of experts in the field of cannabinoid long acting lipid based formulations. This patent is the basis for the company’s “CANNABICS SR” technology, which consists of the IP for standardized and long acting medical cannabis capsules, designed for patients suffering from diverse indications. Simultaneously this Patent was filed with the PCT division of the Israeli Patent Office (ILPO) in order to provide International IP protection. On February 24, 2016 Cannabics pharmaceuticals filed a new patent application for the company’s slow release capsules.
Last year Cannabics opened a genetics lab. This Tel Aviv cannabis research laboratory will focus on developing diagnostic tools based on the human genome, tumor genetics, and cannabinoids.
Cannabics has been immersed in pharmaceutical R&D through their subsidiary Grin Ultra, a licensed Israeli company since 2014. Since that year the Israeli Ministry of Health has granted them the go-ahead for cannabinoid based research. Their research is based on developing cannabinoid medicine specifically for cancer patients. Currently, they administer cannabis in pill form to cancer patients as a treatment for their lack of appetite in one ongoing clinical study. In the wings are two more studies mean to help ease the devastating symptoms of cancer treatment.
To Find out the inside Scoop on CNBX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Both the company and their Laboratory are broadly licensed by the Ministry of Health in Israel specifically for R&D on Cannabis. We see great potential in scientific collaborations with like-minded companies that are engaged in cannabinoid medicines and diagnostics. Currently, we are in the final stages of finalizing our agreement with a company engaged in ophthalmic disorders to develop a product to compete with Steroids in the ocular disease market.
CNBX team of scientists are diligently working to develop and expand our intellectual property portfolio. As such we are waiting for numerous approvals from various national level registrations on our Cannabinoid – Cancer screening patents.
Earlier this month CNBX said it has been granted its patent for its core technology by the Israeli Patent Office. This patent encompasses the systems and methods required to produce data on the interaction between different cannabinoids and cancer cells. This technology enables screening the effects of a multitude of compounds derived from the cannabis plant on cancer cell lines and biopsies. This technology will facilitate the development of more accurate cannabinoid compounds designated for specific cancers and specific genetic profile of patients, at the same time serving as supportive data for cannabinoid-based treatments.
On September 14 CNBX announced it has received encouraging results in its preclinical study showing one of its proprietary cannabinoid compounds causing higher rate of cancer cell death compared to traditional chemotherapy.
Cannabics is rapidly expanding its database of cancer and cannabinoids and established a library of cannabinoid compounds to explore the biological versatility and entourage effect. Recently the company has been granted a patent in Israel on its core technology of screening the effectiveness of cannabis compounds on human biopsies. The research and development center, in Israel, has leveraged its capabilities and accomplished the implementation of the patented technology.
Dr. Eyal Ballan, Co-founder and CTO, said: “I am excited to share the positive results and hope for meaningful collaborations with industry leaders in cancer treatment. There is an advantage in developing cannabis medicine since we explore compounds that are been delivered to patients worldwide and to fine tune the antitumor potential in such a dispersed treatment has a promising value.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $96 million market valuation CNBX has $2.2 million in the treasury, very little debt and tiny revenues so far. CNBX is an exciting story developing in small caps; focused on being the leader in personalized cannabinoid medicine focused on cancer and its side effects, with a team of scientists diligently working to develop and expand their intellectual property portfolio. CNBX stock has a long history of big moves and has been largely ignored in recent months as the rest of the cannabis sector has been booming! Investors in CNBX are betting this is about to change. We will be updating on CNBX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CNBX.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in CNBX either long or short and we have not been compensated for this article.